- Substrate Envelope Hypothesis
- Contact Us
|Celia A. Schiffer, PhD - Principle Investigator|
|Mohan Somasundaran, PhD - Associate Professor
Akbar Ali, PhD - Research Associate Professor
My research is devoted to the discovery and development of small molecule therapeutics against drug-resistant pathogens. Under the auspices of Prof. Celia Schiffer, I lead medicinal chemistry efforts in several research projects, involving structure-guided design, chemical synthesis, and structure-activity relationship (SAR) studies of small-molecule inhibitors targeting viral enzymes (HIV-1 protease, HCV NS3/4A protease) and host-virus interactions (Vif-APOBEC).
|Nese Kurt Yilmaz, PhD - Research Assistant Professor|
|Ellen Nalivaika - Senior Research Associate|
|Madhavi Kolli, PhD - Postdoctoral associate
I study the co-evolution of HIV-1 Protease and it’s substrates. Protease resistance mutations that alter inhibitor binding can sometimes also affect substrate binding. Drug-resistant mutations in the protease, especially those in the active site, can compromise both specificity and catalytic capability of the protease, which in turn may exert a selective pressure on the cleavage sites leading to compensatory substitutions. I have analyzed viral sequences from infected patients for mutations within the substrate cleavage sites and their correlation to resistance-associated protease mutations and for the first time observed several instances of substrate co-evolution. Structural studies of the protease-substrate complexes show changes in hydrogen bonds, van der Waal interactions and conformational changes that likely alter catalytic efficiency of the protease. In addition I am also studying how these correlated mutations affect Gag processing and thus, resistance/fitness.
|Janet Paulsen, PhD - Postdoctoral Associate|
|Shivender Shandilya, PhD - Postdoctoral associate|
|Markus-Frederik Bohn, M.Sc. - Visiting PhD student, Nuremberg, Germany
APOBEC3A is an extremely potent DNA mutator that has been shown to involve in degradation of foreign DNA in phagocytic cells and cancer development. AID and/or APOBEC3F/A may also play a significant role in epigenetic reprogramming. Our focus lies on establishing APOBEC3 proteins as host-encoded molecular targets for antiviral strategies by using a structural and biochemical approach. http://www.bananamark.com
|Kuan-Hung Lin - PhD student|
|Kristina Prachanronarong - MD/PhD student|
|Djade Soumana - PhD student
I earned my BS in Biochemistry and Molecular Biology from the University of Massachusetts at Amherst. Currently, I'm a PhD candidate in the Biochemistry and Pharmacology Department here at UMass, where I'm studying the atomic basis for drug resistance in Hepatitis C. With a combinatorial use of structural biology and enzyme kinetics, I'm interested in investigating how of mutations in the HCV NS3 protease confers drug resistance.
|Debra Ann Ragland - PhD student|
|Tania Silvas - PhD student|
|Natalie Tomaszewski - PhD student|
|Ashley Matthew - MD/PhD student|
|Candice Dufour - Administrative Assistant|